tbuckley/cabot-search huggingface dataset:
Intradiaphragmatic cyst: a diagnostic challenge
Authors: M. Greenberg
Journal: JAMA (1974)

CYSTS of the diaphragm have been classified by previous investigators as (1) mesothelial, (2) bronchogenic, and (3) fibrous.<sup>1-4</sup>Such lesions are rare and provide a difficult challenge in differential diagnosis. In this article, we describe a 26-year-old man with mesothelial cyst of the diaphragm, with chronic hemorrhage and inflammation, not associated with trauma. To our knowledge, a few cases of mesothelial cyst of the diaphragm with clear fluid have been reported. Only one description of a case of cystic hematoma of the diaphragm exists and this was defined primarily as hematoma due to trauma with degeneration.<sup>5</sup> <h3>Report of a Case</h3> A 26-year-old man complained of pain in the right side of the abdomen and thorax with radiation to the right shoulder, which began approximately two months before admission. This pain was described as dull aching, with acute exacerbations. There were no associated symptoms, such as nausea, vomiting, or
Colorectal Cancer Yields to Dual HER2 Blockade
Journal: Cancer Discovery (2016)

Abstract According to data from a phase II study, the anti-HER2 combination of trastuzumab and lapatinib is active in patients with KRAS–wild-type, HER2-positive metastatic colorectal cancer. None of the study participants responded to previous, standard treatment with the EGFR inhibitors cetuximab or panitumumab, but 30% achieved an objective response to dual HER2 blockade.
Special Reports, Announcements, and Notices
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Carcinogenicity of Methoxyl Derivatives of 4-Aminoazobenzene: Correlation between DNA Adducts and Genotoxicity
Authors: Misaki Kojima, Masakuni Degawa, Yoshiyuki Hashimoto, Mariko Tada
Journal: Environmental Health Perspectives (1994)

To elucidate the cause of the difference in genotoxic activity between carcinogenic 3-methoxy-4-aminoazobenzene (3-MeO-AAB) and noncarcino- genic 2-methoxy-4-aminoazobenzene (2-MeO-AAB), we analyzed DNA adducts in the livers of rats exposed to either of these chemicals and studied the resulting biologic potential with the aid of in vitro modified M13 phage DNA.32P-Postlabeling analysis revealed that the carcinogen 3-MeO-AAB produced 20-fold higher amounts of adducts than did 2-MeO-AAB.Five adducts were formed in the 3-MeO-AAB case whereas only one adduct was apparent in 2-MeO-AAB-treated rat.Studies of in vitro DNA replication using N-hydroxy (N-OH)-aminoazo dye-modified Ml 3 phage DNA as a template demonstrated inhibition by 3-MeO-AAB adducts to be substantially greater than in the 2-MeO-AAB-adducts.The specificity of mutagenesis induced in M13mp9 phage DNA by these chemicals also was analyzed after transfection into SOS-induced Escherichia co/i JM103, mutation frequencies being higher with N-OH-3-MeO-AAB-than N-OH-2-MeO-AAB-modified DNA.The mutation spectra differed in each case.Our data suggest that the difference in hepatocarcinogenic activity between the two chemicals depends not only on qualitative and quantitative variation in adduct for- mation but also on conformation changes in modified DNA.-
Glibenclamide attenuates peaked T wave in early phase of myocardial ischemia
Authors: T. Kondo, I. Kubota, H. Tachibana, M. Yamaki, H. Tomoike
Journal: Cardiovascular Research (1996)

ECG peaked T wave appears during the early phase of myocardial ischemia, but the underlying mechanisms remain unknown. The purpose of this study was to elucidate the role of ATP-sensitive K+ channel (KATP) in this ECG change. In 12 anesthetized, open-chest dogs, the sinus node was crushed and the right atrium was paced at a cycle length of 400 ms. The left anterior descending coronary artery was abruptly occluded for 60 s before (control) and 15 min after an intravenous infusion of vehicle (n = 6) or glibenclamide (1 mg/kg, n = 6), a blocker of KATP. Forty-eight epicardial electrograms were simultaneously recorded from the anterior surface of the left ventricle. The potentials at 40, 80 and 120 ms from the J point were measured, and these points corresponded to the early, middle and late phases of the T wave, respectively. During the control occlusion, T wave increased time-dependently and the maximal T-wave change was noted at the end of 60 s of coronary occlusion. The extents of T-wave elevation at the early, mid and late T phases were 5.5 ± 0.5, 7.3 ± 0.8 and 11.7 ± 1.8 mV, respectively, and these T-wave elevations were significantly reduced by 33 ± 21%, 59 ± 12% and 63 ± 13%, respectively, after the pretreatment with glibenclamide but not with its vehicle. The % reductions of mid and late T by glibenclamide were significantly larger than that of early T wave (P < 0.05). An abrupt coronary occlusion accompanied peaked T wave as an early ECG wave change. As the extent of this T-wave elevation was attenuated by glibenclamide, the ischemia-induced alteration of ventricular repolarization can partly (60%) be explained by the modification of KATP activation.
FOLFIRINOX in locally advanced or metastatic pancreatic cancer.
Authors: Jason Edward Faris, Theodore S. Hong, Shaunagh McDermott, Alexander R Guimaraes, Dushyant Sahani, Jeffrey W. Clark, David P. Ryan, Lawrence Scott Blaszkowsky
Journal: Journal of Clinical Oncology (2012)

313 Background: The recently published Phase III trial of 5-FU, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) demonstrated improved survival compared to gemcitabine in good performance status (PS) patients with metastatic pancreatic cancer (Conroy et al, NEJM 2011). Less is known about the efficacy and tolerability with FOLFIRINOX in the non-clinical trial setting. In this retrospective analysis, we report our institutional experience with FOLFIRINOX. Methods: 29 patients with locally advanced or metastatic pancreatic cancer treated with FOLFIRINOX between July 2010 and April 2011 were used for this analysis. Clinical characteristics, and gradeable toxicities were tabulated, and formal radiographic review performed to determine best overall response rates (ORR). Results: 17 patients received FOLFIRINOX for metastatic disease and 12 patients for locally advanced disease. The median age of patients was 60 (range 39-76). 22/29 patients were men. 18/29 patients had received no prior chemotherapy. There was one patient with PS 2; all others had PS 0 or 1. 8/29 patients had biliary stents. Overall, 11 partial responses (PR) were observed (ORR 38%); 10/11 partial responses were in chemo-naïve patients, who had an ORR of 56%. In the metastatic setting, there were 6 PR, for an ORR of 35%, and 7 patients with stable disease (SD). In the locally advanced setting, there were 5 PR (ORR 42%), and 7 patients with SD. Following treatment with FOLFIRINOX, one patient with locally advanced disease has subsequently undergone R0 resection. The median number of cycles performed was 8 in both the locally advanced and metastatic settings. 12/29 patients required an ED visit or hospitalization during treatment. Grade 3/4 neutropenia was observed in 10 patients; 7/10 had not received prophylactic growth factor treatment from the start of FOLFIRINOX. 4 patients developed febrile neutropenia, 4 patients developed grade 3/4 thrombocytopenia, and 1 patient developed grade 4 anemia. Conclusions: In a non-clinical trial setting, FOLFIRINOX demonstrated activity in both the metastatic and locally-advanced settings. FOLFIRINOX appears to be associated with manageable, but significant toxicities, with over 40% of patients requiring hospitalization.
Homicidal Threats
Authors: JOHN M. MACDONALD
Journal: American Journal of Psychiatry (1967)

Although homicidal threats are more often made than carried out, the necessity for assessment of risk and the implementation of preventive measures when such threats are made are apparent. The author examines the incidence of potential predictors of homicide among three groups—hospital patients who have made threats to kill, convicted homicide offenders, and a control group of hospital patients who have no history of homicidal behavior.
Manuscripts Approved for JNCI During February–March 1976
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Manuscripts Approved for JNCI During February–March 1976 Get access JNCI: Journal of the National Cancer Institute, Volume 56, Issue 4, April 1976, Pages 875–876, https://doi.org/10.1093/jnci/56.4.875-a Published: 01 April 1976
FURTHER STUDIES ON THE SPECIFICITY OF STREPTOCOCCI
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rituximab Maintenenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma - Results of a Multicenter Prospective Randomised Phase II Study.
Authors: Mathias Witzens-Harig, Manfred Hensel, Johann W. Schmier, Kai Neben, Axel Benner, Peter Dreger, Christian Kuhn, Ingo Schmidt-Wolf, Alwin Krämer, Anthony D. Ho
Journal: Blood (2006)
SEER analysis of outcomes for primary small cell carcinoma of the ovary.
Authors: OMER HASSAN JAMY, George Yaghmour, Felicia Hare, Jason Claud Chandler, Sundae Stelts, Laleh Azari, Michael Gary Martin
Journal: Journal of Clinical Oncology (2014)

e16512 Background: Primary small cell carcinoma of the ovary (SCCO) is rare, making prognosis and outcomes largely undefined. Methods: Using case listing session of SEER 18 (1973-2010) we examined outcomes for patients (pts) with SCCO. Analyses were conducted with SEER*Stat 8.1.2, Microsoft Excel 2007 and GraphPad Prism 6. Comparisons were made using the chi-squared test and log rank test (Mantel-Cox); all p-values were 2-sided. Results: 181 pts with primary SCCO with staging were identified; median age was 37 (range 10-91). 29 (15%) had localized disease (dz), 19 (11%) had regional dz and 133 (74%) had distant dz. 100% of pts with localized dz and 95% of pts with regional dz had surgery. Median overall survival (OS) varied by stage (67 months [m] v 12m v 9m, p<0.001). Radiation was rarely used in localized (1 pt, 3%) or regional disease (3 pts, 16%). For comparison 81,933 cases of small cell lung cancer (SCLC) were identified from the same database with a median age of 68; 8% localized, 29%regional and 63% distant dz. Outcomes were superior for pts with SCCO with localized dz (67m v 16m, p<0.001) and distant dz (9m v 7m, p<0.001) but were similar in pts with regional dz (12m v 13m, p=0.675). Conclusions: SCCO presents at a younger age than SCLC but has a similar stage distribution. Pts with localized SCCO have a more favorable prognosis than patients with SCLC, but patients with regional and distant dz have similar outcomes.
Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group
Authors: W. G. Walker
Journal: JAMA (1992)

<h3>Objective.</h3> —To evaluate the contribution of mild to moderate hypertension to progressive loss of renal function by analysis of renal function data from the Multiple Risk Factor Intervention Trial. <h3>Design.</h3> —The cohort of men with mild to moderate hypertension (baseline diastolic blood pressure ≥90 mm Hg), randomized to a special intervention (SI) group or usual care (UC) group, were examined for change in renal function based on individual reciprocal creatinine slopes over an average of 7 years' follow-up as the outcome measure. Contribution of blood pressure control during follow-up, age, race, and blood pressure at entry were assessed. <h3>Participants.</h3> —The cohort of 5524(463 black, 5061 nonblack) hypertensive men receiving no therapy at entry provided the data for the present analysis. <h3>Results.</h3> —Blood pressure control was similar for black and white participants, but significant decline in reciprocal creatinine slope was found for black men (mean slope, —0.0090±0.0013 dL/mg/y) compared with white men (+0.0018± 0.0004 dL/mg/y) (<i>P</i>&lt;.001 for difference between blacks and whites). Decline in renal function was also greater among individuals with elevated systolic (<i>P</i>&lt;.001) as well as diastolic blood pressure (<i>P</i>&lt;.001), and older individuals (<i>P</i>&lt;.001). No difference between the SI and UC groups was seen in reciprocal creatinine slopes, but in both groups combined, treatment that maintained diastolic blood pressure below an average value of 95 mm Hg was associated with stable or improving renal function, whereas participants whose blood pressure remained 95 mm Hg or greater continued to decline at —0.0013±0.0009 dL/mg/y (<i>P</i>=.007 for difference). Separate examination of the subset of black men (n=463) failed to show such a difference. <h3>Conclusions.</h3> —Effective blood pressure control was associated with stable or improving renal function in nonblacks but not in blacks. These findings emphasize the importance of blood pressure control to maintain adequate renal function in hypertensive white men and raise important questions about the relationship of pressure reduction and renal function change in blacks. (<i>JAMA</i>. 1992;268:3085-3091)
MENTAL DISEASES AND GENERAL PRACTICE.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diabetes as a Tracer Condition in International Benchmarking of Health Systems
Authors: E. Nolte
Journal: Diabetes Care (2006)

RESEARCH DESIGN AND METHODS—We generated a measure of "case-fatality" among young people with diabetes using the mortality-to-incidence ratio (M/I ratio) for 29 industrialized countries using published data on diabetes incidence and mortality. Standardized incidence rates for ages 0–14 years were extracted from the World Health Organization DiaMond study for the period 1990–1994; data on death from diabetes for ages 0–39 years were obtained from the World Health Organization mortality database and converted into age-standardized death rates for the period 1994–1998, using the European standard population.
Targeted Inhibition of PI3K α/δ Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCL
Authors: Kamil Bojarczuk, Kirsty Wienand, Jeremy A. Ryan, Linfeng Chen, Mariana Villalobos-Ortiz, Elisa Mandato, Joanna Stachura, Lee N. Lawton, Anthony Letai, Bjoern Chapuy, Margaret A. Shipp
Journal: Blood (2018)
NO SHORT CUTS TO EXCELLENCE
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TRAUMATIC ENDOCARDITIS.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In This Issue
Journal: Journal of Clinical Investigation (2009)

Human resistin contributes to insulin resistanceThe development of insulin resistance in individuals who are obese is linked to many factors, including dysregulated production of adipocyte-derived factors (adipokines).Although the adipokine resistin clearly contributes to the development of insulin resistance in mice, previous studies failed to determine such a clear association in humans.One confounding factor is that resistin is produced mainly by macrophages in humans, whereas it is produced by adipocytes in mice.To overcome this issue, Qatanani and colleagues generated humanized resistin mice, which lack mouse resistin and express human resistin in macrophages (531-539).When fed a high-fat diet, these mice developed white adipose tissue inflammation more rapidly than did control mice, and this was associated with accelerated lipid dysregulation and insulin resistance.The exacerbated insulin resistance in humanized resistin mice was caused by lipid accumulation in skeletal muscle, which induced activation of the Pkcθ signaling pathway and subsequent serine phosphorylation of Irs-1.The authors therefore conclude that mouse and human resistin, although produced by different cells, both contribute to the development of insulin resistance.They further suggest that resistin probably constitutes an important link between obesity, inflammation, and insulin resistance in humans.
Abstract 4236: Evaluating alterations in mRNA biogenesis with TCGA breast cancer sequencing data
Authors: Thomas J. Yan, Matthew E. Burow, Elizabeth C. Martin
Journal: Cancer Research (2019)

Abstract Alternative splicing leads to the production of multiple mRNA isoforms of a gene transcript with distinct functional characteristics. These events are frequently observed in rapidly dividing cancer cells and are broadly recognized as important signatures for oncogenesis pathways and treatment options. In this study, we utilized data from The Cancer Genome Atlas (TCGA) to identify differences in isoform expression between estrogen receptor-positive and estrogen receptor-negative breast cancer cell lines. RNA sequencing analysis combined with clinical annotation data revealed alterations in isoform expression that were associated with patient survival. These global changes in isoform expression occurred independently of total gene expression in both estrogen receptor-positive and -negative breast cancer. Furthermore, we identified multiple underrepresented isoforms including CDKAL1 and CSTF3 that were associated with favorable prognostic outcomes despite a lack of association observed with their traditional transcripts. These data suggest an underlying role mediated by alternative spliced isoforms in driving clinical outcome in breast cancer, warranting further investigation in delineating isoform expression profiles in previously established cancer pathways. Citation Format: Thomas J. Yan, Matthew E. Burow, Elizabeth C. Martin. Evaluating alterations in mRNA biogenesis with TCGA breast cancer sequencing data [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4236.